Highlights Biosergen AB

Equities

BIOSGN

SE0016013460

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 19/06/2024 pm IST			5-day change	1st Jan Change
0.319 ^SEK	+4.25%		+3.24%	-63.75%

14/06	Biosergen AB Approves Board Changes	CI
11/06	Biosergen AB Receives the Final Permission Required to Test Lead Candidate BSG005 in Patients with Invasive Fungal Infection	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biosergen AB Receives the Final Permission Required to Test Lead Candidate BSG005 in Patients with Invasive Fungal Infection	11/06	CI
Biosergen AB Reports Earnings Results for the First Quarter Ended March 31, 2024	31/05	CI
Biosergen AB Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy	12/02	MT
Biosergen AB Receives Regulatory Approval to Test Lead Candidate Bsg005 in Patients with Invasive Fungal Infection	12/02	CI
Biosergen AB Announces CEO Changes	12/01	CI
Biosergen AB Announces Transition of Peder M. Andersen into A Chief Medical Officer Role	12/01	CI
Biosergen Conducts A New Phase 1B Study in Patients with Invasive Fungal Infections with Its Drug Candidate Bsg005 Together with Alkem	12/01	CI
Biosergen's Indian Partner Seeks Approval for Clinical Trial of Antifungal Drug Candidate	12/12	MT
Biosergen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30/11	CI
Biosergen AB Announces Abstract About the Drug Candidate BSG005	23/23/23	CI
Alkem Laboratories Limited and Biosergen AB Enter into a Co-Development and License Agreement	25/23/25	CI
Biosergen AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Biosergen AB Reports Earnings Results for the First Quarter Ended March 31, 2023	31/23/31	CI
Biosergen Provides Phase 2 Clinical Development Strategy Update	29/23/29	CI
Biosergen AB announces Positive Topline Data from Phase 1 Study of Bsg005 Shows It Is Safe and Well Tolerated. It Gives Hope for A Change in the Treatment Paradigm of Patients with Invasive Fungal Infections	13/23/13	CI
Biosergen Completes the First Multiple Ascending Dose Cohort of BSG005 Phase I Trial	16/23/16	CI
Biosergen AB Announcest First Volunteer Has Been Dosed in the Mad Part of the Phase I Trial of BSG005	12/22/12	CI
Biosergen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	30/22/30	CI
Biosergen AB Moves into Multiple Ascending Dose Part of Its Phase I Study After 4 Cohorts Tested in the SAD Part of Study	08/22/08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Biosergen AB

Equities

BIOSGN

SE0016013460

Highlights

Filters